Cure My Disease

Don't miss your cure!

 Log in / Sign up

Electric pulses and sound waves may rebuild muscle after stroke

NCT ID NCT07708597

Disease control Sponsor: Nanjing First Hospital, Nanjing Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This trial investigates whether combining neuromuscular electrical stimulation (NMES) with therapeutic ultrasound can help stroke patients who also have sarcopenia—a condition of low muscle mass and strength. Participants receive four weeks of daily therapy, and researchers measure changes in muscle thickness, grip strength, and physical function. The goal is to see if the combo works better than standard rehab alone.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
neuromuscular electrical stimulation and therapeutic ultrasound
What this could lead to
If successful, this combination therapy could offer a new way to restore muscle and function in stroke survivors with muscle wasting.
What could go wrong
This is a small, early-phase trial with 152 participants, so results may not apply broadly. The therapy is time-intensive and may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 152 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of first-ever stroke confirmed by CT or MRI, with stable vital signs, disease course between 3 weeks and 6 months. Diagnosis of sarcopenia according to the 2019 Asian Working Group for Sarcopenia (AWGS) criteria: reduced handgrip strength (male \< 28 kg, female \< 18 kg) and/or gait speed \< 1.0 m/s, and reduced appendicular skeletal muscle mass index (male \< 7.0 kg/m², female \< 5.4 kg/m²). Age between 30 and 75 years. Brunnstrom stage of affected upper and lower limbs ≥ III, and modified Ashworth scale ≤ 2. No significant consciousness or cognitive impairment. Willing and able to provide written informed consent. Exclusion Criteria: * Presence of significant emotional or cognitive impairment. Obesity or overweight (body mass index \> 25 kg/m²). Unable to stand up from a chair with or without assistance. Comorbidities including renal, hepatic, or heart failure.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Sarcopenia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Sarcopenia stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Sarcopenia Stroke

Contacts and locations

Locations

  • Nanjing First Hospital

    Nanjing, Jiangsu, 2100061, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.